Publicaciones (79) Publicaciones de LUIS ALBERTO MENCHÉN VISO

2024

  1. Controversies in the management of anti-TNF therapy in patients with Crohn's disease: a Delphi consensus

    BMJ Open Gastroenterology, Vol. 11, Núm. 1

  2. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU

    Revista espanola de enfermedades digestivas, Vol. 116, Núm. 2, pp. 83-113

  3. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432

2023

  1. Akkermansia deficiency and mucin depletion are implicated in intestinal barrier dysfunction as earlier event in the development of inflammation in interleukin-10-deficient mice

    Frontiers in Microbiology, Vol. 13

  2. Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

  3. Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP

    Journal of Clinical Medicine, Vol. 12, Núm. 14

  4. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

    Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 3, pp. 771-788.e10

  5. Immune System and Brain/Intestinal Barrier Functions in Psychiatric Diseases: Is Sphingosine-1-Phosphate at the Helm?

    International Journal of Molecular Sciences, Vol. 24, Núm. 16

  6. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

    American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247

  7. Single nucleotide polymorphisms in ADAM17, IL23R and SLCO1C1 genes protect against infliximab failure in adults with Crohn's disease

    Biomedicine and Pharmacotherapy, Vol. 159

  8. Splanchnic Vein Thrombosis in Inflammatory Bowel Disease: An Observational Study from the ENEIDA Registry and Systematic Review

    Journal of Clinical Medicine, Vol. 12, Núm. 23

  9. Transmural or mucosal healing in Crohn´s disease. Which is the goal to be pursued?

    Revista espanola de enfermedades digestivas, Vol. 115, Núm. 6, pp. 289-291

2022

  1. Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 1, pp. 73-83

  2. Design and implementation of a mobile app for the pharmacotherapeutic follow-up of patients diagnosed with immune-mediated inflammatory diseases: eMidCare

    Frontiers in Immunology, Vol. 13

  3. ECCO Topical Review on Clinicopathological Spectrum and Differential Diagnosis of Inflammatory Bowel Disease

    Journal of Crohn's & colitis, Vol. 16, Núm. 3, pp. 343-368

  4. Information and Communication Technologies in Patients With Immune-Mediated Inflammatory Diseases: Cross-sectional Survey

    Journal of medical Internet research, Vol. 24, Núm. 9, pp. e37445

  5. Lentinula edodes extract increases goblet cell number and Muc2 expression in an intestinal inflammatory model of Trichinella spiralis infection

    Biomedicine and Pharmacotherapy, Vol. 150

  6. Sphk2 deletion is involved in structural abnormalities and Th17 response but does not aggravate colon inflammation induced by sub-chronic stress

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 198

  2. Histological inflammatory activity can predict endoscopic relapse in patients with ulcerative colitis who have achieved mucosal healing

    European journal of gastroenterology & hepatology, Vol. 33, Núm. 1S Suppl 1, pp. e796-e802